Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, progressive, and potentially fatal disease caused by abnormal deposits of transthyretin amyloid protein in the heart. Transthyretin, also called prealbumin, is a protein produced in the liver and transportation various hormones and vitamins. When transthyretin is mutated or damaged, it can unfold and accumulate as amyloid fibrils in various tissues including heart, limbs, digestive system and peripheral nervous system. Symptoms of ATTR-CM include shortness of breath, leg swelling, fatigue, dizziness, arrhythmias and others. Growing awareness about ATTR-CM and adoption of advanced diagnostic technologies is facilitating early diagnosis and treatment of the disease. Several pharmacological therapies are currently under clinical trials to address treatment gaps in ATTR-CM management.
Key Takeaways
Key players operating in the transthyretin amyloid cardiomyopathy treatment market are DermaSweep Inc., Lifetrons Switzerland AG, Trophy Skin,PMD Beauty, Dermaglow, ImageDerm Inc., Clairderm Medical Aesthetics, Sylvan Company, Altair Instruments, Koninklijke Philips, Microderm GLO Skincare USA, Silhouet-Tone, and Edge Systems LLC. (HydraFacial), among others. Major players are engaged in new product development and increasing investments in R&D to develop advanced therapeutics. For instance, Alnylam Pharmaceuticals received FDA approval for Onpattro (patisiran) in 2018, the first-ever RNAi therapeutic for ATTR amyloidosis with polyneuropathy.
Increasing investment in research related to early diagnosis and treatment of ATTR-CM present significant growth opportunities in the market. Development of novel diagnostics, biomarkers and genetic testing will aid in timely diagnosis and management. Widening access to advanced treatment options in developing regions will further expand the global reach of major players.
Key players are adopting strategies like collaborations, mergers and acquisitions to strengthen their product portfolio and geographical presence. For example, in 2021, Eidos Therapeutics was acquired by BridgeBio Pharma to gain access to their investigative ATTR therapeutics agbx-100 and agbx-113.
Market Drivers and Restraints
Growing prevalence of hereditary and wild-type ATTR amyloidosis is a major market driver. Rising geriatric populations susceptible to age-related amyloidosis also contributes to the increasing disease burden. Significant unmet needs in ATTR-CM management amplifies the demand for novel pharmacological therapies. Major pharmaceutical companies are accelerating their R&D efforts in this domain, encouraged by the positive outcomes of ongoing clinical trials.
High costs of treatment pose a major challenge to market growth. Novel ATTR-CM drugs are likely to be highly priced. Limited awareness regarding the condition also results in underdiagnosis and patients not receiving optimal care. Stringent regulatory frameworks further delay market introduction of new ATTR therapeutics. However, ongoing awareness initiatives by patient advocacy groups and increasing acceptance of orphan drugs are expected to mitigate some of these restraints over the forecast period.
Segment Analysis
The Transthyretin Amyloid Cardiomyopathy Treatment Market Demand can be segmented on the basis of drug type into diflunisal, tafamidis, and others. Among these, tafamidis dominates the market as it is the first FDA approved medication for transthyretin amyloid cardiomyopathy and has shown promising results in slowing down the condition's progression without major side effects. It accounted for over 50% of the overall market share in 2024.
Global Analysis:
The North American region dominated the global transthyretin amyloid cardiomyopathy treatment market in 2024 and accounted for near 40% of the total market share. This is attributed to the growing prevalence of ATTR-CM combined with expanding diagnostic services within the region. The region is also witnessing rising awareness about rare diseases such as transthyretin amyloid cardiomyopathy. However, going forward, the Asia Pacific region will witness the highest growth due to the improving healthcare infrastructure, rising income levels, and growing focus of international medical devices companies on establishing their presence in emerging countries. Countries like China and India are expected to offer several growth opportunities for market players in the coming years.
Get more insights on Transthyretin Amyloid Cardiomyopathy Treatment Market
Comments
0 comment